US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

BIIB

Biogen (BIIB)

Biogen Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BIIB

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
02/05/2024	06:30	GlobeNewswire Inc.	Biogen Reports Progress on Corporate Responsibility Priorities	NASDAQ:BIIB	Biogen Inc
31/03/2024	18:30	PR Newswire (US)	Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	NASDAQ:BIIB	Biogen Inc
06/03/2024	06:30	GlobeNewswire Inc.	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy	NASDAQ:BIIB	Biogen Inc
04/03/2024	15:15	GlobeNewswire Inc.	Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting	NASDAQ:BIIB	Biogen Inc
26/02/2024	18:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
23/02/2024	06:00	GlobeNewswire Inc.	Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP	NASDAQ:BIIB	Biogen Inc
22/02/2024	09:12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BIIB	Biogen Inc
13/02/2024	06:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIIB	Biogen Inc
12/02/2024	18:11	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:BIIB	Biogen Inc
12/02/2024	15:06	GlobeNewswire Inc.	Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia	NASDAQ:BIIB	Biogen Inc
09/01/2024	16:52	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
19/12/2023	06:30	GlobeNewswire Inc.	Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission	NASDAQ:BIIB	Biogen Inc
15/12/2023	08:05	GlobeNewswire Inc.	CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease	NASDAQ:BIIB	Biogen Inc
14/12/2023	05:30	Business Wire	ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.	NASDAQ:BIIB	Biogen Inc
08/11/2023	15:35	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BIIB	Biogen Inc
08/11/2023	07:19	IH Market News	Keep An Eye Out: Pre-Market Movers And Analyst Recommendations	NASDAQ:BIIB	Biogen Inc
06/11/2023	16:44	KR Market News	월스트리트 상승, 시장은 연준 연사 및 재무부 경매 주목	NASDAQ:BIIB	Biogen Inc
06/11/2023	06:30	GlobeNewswire Inc.	Biogen Appoints Monish Patolawala to its Board of Directors	NASDAQ:BIIB	Biogen Inc
26/10/2023	06:08	IH Market News	Thursday’s Wall Street Highlights: Ford, Morgan Stanley, Align Technology, Endeavor, and more	NASDAQ:BIIB	Biogen Inc
25/10/2023	16:26	GlobeNewswire Inc.	Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alz	NASDAQ:BIIB	Biogen Inc
25/10/2023	16:25	PR Newswire (US)	EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHE	NASDAQ:BIIB	Biogen Inc
25/10/2023	09:51	GlobeNewswire Inc.	New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease	NASDAQ:BIIB	Biogen Inc
24/10/2023	08:30	PR Newswire (US)	LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023	NASDAQ:BIIB	Biogen Inc
19/10/2023	06:30	GlobeNewswire Inc.	Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting	NASDAQ:BIIB	Biogen Inc
04/10/2023	07:15	IH Market News	Keep An Eye Out: Pre-Market Movers And Recommendations	NASDAQ:BIIB	Biogen Inc
29/09/2023	15:49	Dow Jones News	Biogen's Tofidence Intravenous Formulation Gets FDA Approval	NASDAQ:BIIB	Biogen Inc
29/09/2023	15:06	GlobeNewswire Inc.	FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®	NASDAQ:BIIB	Biogen Inc
28/09/2023	16:25	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:BIIB	Biogen Inc
26/09/2023	07:59	GlobeNewswire Inc.	Biogen Completes Acquisition of Reata Pharmaceuticals	NASDAQ:BIIB	Biogen Inc
25/09/2023	00:02	GlobeNewswire Inc.	LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan	NASDAQ:BIIB	Biogen Inc

Showing the most relevant articles for your search:NASDAQ:BIIB

1 2 3 4 5 6 7 8 9 10 Próxima >

JP Morgan Chase

US Dollar vs MXN

Verizon Communications

Invesco QQQ Trust Series 1

Gold vs US Dollar

Bank of America

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones